Biomedical Engineering Reference
In-Depth Information
Koehbach J, O'Brien M, Muttenthaler M, Miazzo M, Akcan M, Elliott AG, Daly NL, Harvey PJ,
Arrowsmith S, Gunasekera S, Smith TJ, Wray S, Goransson U, Dawson PE, Craik DJ, Fre-
issmuth M, Gruber CW (2013) Oxytocic plant cyclotides as templates for peptide G protein-
coupled receptor ligand design. Proc Natl Acad Sci U S A 110(52):21183-21188. doi:10.1073/
pnas.1311183110
Maksimov MO, Link AJ (2013) Discovery and characterization of an isopeptidase that linearizes
lasso peptides. J Am Chem Soc 135(32):12038-12047. doi:10.1021/ja4054256
Maksimov MO, Pelczer I, Link AJ (2012) Precursor-centric genome-mining approach for lasso
peptide discovery. Proc Natl Acad Sci U S A. doi:10.1073/pnas.1208978109
Pan SJ, Link AJ (2011) Sequence diversity in the lasso peptide framework: discovery of functional
microcin J25 variants with multiple amino acid substitutions. J Am Chem Soc 133(13):5016-
5023. doi:10.1021/ja1109634
Pavlova O, Mukhopadhyay J, Sineva E, Ebright RH, Severinov K (2008) Systematic structure-
activity analysis of microcin J25. J Biol Chem 283(37):25589-25595
Poth AG, Chan LY, Craik DJ (2013) Cyclotides as grafting frameworks for protein engineering and
drug design applications. Biopolymers 100(5):480-491. doi:10.1002/bip.22284
Salomón RA, Farías RN (1992) Microcin 25, a novel antimicrobial peptide produced by
Escherichia coli
. J Bacteriol 174(22):7428-7435
Sato AK, Viswanathan M, Kent RB, Wood CR (2006) Therapeutic peptides: technological advances
driving peptides into development. Curr Opin Biotechnol 17(6):638-642. doi:10.1016/j.cop-
bio.2006.10.002
Severinov K, Semenova E, Kazakov A, Kazakov T, Gelfand MS (2007) Low-molecular-weight
post-translationally modified microcins. Mol Microbiol 65(6):1380-1394
Shibata K, Suzawa T, Ohno T, Yamada K, Tanaka T, Tsukuda E, Matsuda Y, Yamasaki M (1998)
Hybrid peptides constructed from RES-701-1, an endothelin B receptor antagonist, and endo-
thelin; binding selectivity for endothelin receptors and their pharmacological activity. Bioorg
Med Chem 6(12):2459-2467. doi:S0968089698800205
Shibata K, Suzawa T, Soga S, Mizukami T, Yamada K, Hanai N, Yamasaki M (2003) Improvement
of biological activity and proteolytic stability of peptides by coupling with a cyclic peptide.
Bioorg Med Chem Lett 13(15):2583-2586. doi:S0960894X03004761
Sommerhoff CP, Avrutina O, Schmoldt HU, Gabrijelcic-Geiger D, Diederichsen U, Kolmar H
(2010) Engineered cystine knot miniproteins as potent inhibitors of human mast cell tryptase
beta. J Mol Biol 395(1):167-175. doi:10.1016/j.jmb.2009.10.028
Soudy R, Wang L, Kaur K (2012) Synthetic peptides derived from the sequence of a lasso peptide
microcin J25 show antibacterial activity. Bioorg Med Chem 20(5):1794-1800. doi:10.1016/j.
bmc.2011.12.061
Thongyoo P, Bonomelli C, Leatherbarrow RJ, Tate EW (2009) Potent inhibitors of beta-tryptase
and human leukocyte elastase based on the MCoTI-II scaffold. J Med Chem 52(20):6197-
6200. doi:10.1021/jm901233u
Twomey D, Ross RP, Ryan M, Meaney B, Hill C (2002) Lantibiotics produced by lactic acid
bacteria: structure, function and applications. Antonie Van Leeuwenhoek 82(1-4):165-185
Willey JM, van der Donk WA (2007) Lantibiotics: peptides of diverse structure and function. Annu
Rev Microbiol 61:477-501. doi:10.1146/annurev.micro.61.080706.093501
Wong CT, Rowlands DK, Wong CH, Lo TW, Nguyen GK, Li HY, Tam JP (2012) Orally ac-
tive peptidic bradykinin B1 receptor antagonists engineered from a cyclotide scaffold for
inflammatory pain treatment. Angew Chem Int Ed Engl 51(23):5620-5624. doi:10.1002/
anie.201200984
Zimmermann M, Hegemann JD, Xie X, Marahiel MA (2013) The astexin-1 lasso peptides: bio-
synthesis, stability, and structural studies. Chem Biol 20(4):558-569. doi:10.1016/j.chembi-
ol.2013.03.013